* Active or currently treated or \<1 year diagnosed cancer
* Active or currently treated or \<1 year diagnosed malignant blood disease
* Immunosuppressive treatment observed for more than 1 month
Laboratory confirmed SARS-CoV2 infection with mild COVID-19, fulfilling all the following criteria:
* Positive SARS-CoV-2 RT-PCR nasal swab samples AND
* Clinical symptoms and signs consistent with SARS-CoV2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia…(1)
Informed consent to participate to the trial
Patients must be able and willing to comply with study visits and procedures
You may not be if
Initial need for hospitalization for COVID-19 management
Pregnancy and breastfeeding
Participation to another interventional drug trial
Subject protected by law under guardianship or curatorship
Absence of health insurance
Known hypersensitivity to camostat mesylate
Known person sharing the same household already included in the study
Participation to another COVID-19 ambulatory interventional study
Patients having completed a full SARS-CoV2 vaccine immunization procedure less than 4 weeks prior to COVID-19 diagnosis (last vaccine injection performed less than 4 weeks prior to COVID-19 diagnosis)
Clareo Health | CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
